Anti-Axl antibodies
Antibodies which specifically bind to the Ax I protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
1. An isolated antibody that binds Axl, wherein the antibody comprises a heavy chain variable region (VH) that comprises a VH complementarity determining region (VH CDR) 1 with the amino acid sequence of SEQ ID NO: 5, a VH CDR2 with the amino acid sequence of SEQ ID NO: 6, and a VH CDR3 with the amino acid sequence of SEQ ID NO: 7, and a light chain variable region (VL) that comprises a VL complementarity determining region (VL CDR) 1 with the amino acid sequence of SEQ ID NO: 8, a VL CDR2 with the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 with the amino acid sequence of SEQ ID NO: 10.
2. The isolated antibody of claim 1 , which is a humanized or chimeric antibody.
3. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain variable region with the amino acid sequence of SEQ ID NO: 3.
4. The isolated antibody of claim 1 , wherein the antibody comprises a light chain variable region with the amino acid sequence of SEQ ID NO: 4.
5. The isolated antibody of claim 3 , wherein the antibody comprises a light chain variable region with the amino acid sequence of SEQ ID NO: 4.
6. The isolated antibody of claim 1 , wherein the antibody is a whole antibody or an antigen-binding fragment.
7. The isolated antibody of claim 6 , wherein the antibody is a monospecific, bispecific, or multispecific antigen binding fragment selected from Fv, scFv, dsFv, Fab, F(ab′)2, minibody, diabody, single-chain diabody, tandem scFv, bi-body, tri-body, or kappa(lambda)-body.
8. The isolated antibody of claim 1 , wherein the antibody binds Axl with a K D no greater than 5×10 −12 M.
9. The isolated antibody of claim 1 , wherein the antibody binds Axl with a k on no lower than 2×10 7 M −1 s −1 .
10. The isolated antibody of claim 1 , wherein the antibody binds human Axl.
11. The isolated antibody of claim 1 , wherein the antibody:
(i) binds murine Axl with a K D greater than 10 −3 M;
(ii) binds human Mer with a K D greater than 10 −3 M; and/or
(iii) binds human Tyro3 with a K D greater than 10 −3 M.
12. The isolated antibody of claim 1 , wherein the antibody is conjugated to a detectable label, enzyme, or toxin.
13. An immunoconjugate comprising the antibody of claim 1 conjugated to a cytotoxic agent.
14. A composition comprising the antibody of claim 1 , or an immunoconjugate thereof, and a pharmaceutically acceptable excipient.
15. The composition of claim 14 , further comprising an immune checkpoint modulator (ICM).
16. An isolated nucleic acid which comprises a nucleotide sequence encoding the heavy chain variable region, the light chain variable region, or the heavy chain variable region and the light chain variable region of the antibody of claim 1 .
17. An isolated host cell transformed with the nucleic acid of claim 16 .
18. A method of producing a heavy chain variable region, a light chain variable region, or a heavy chain variable region and a light chain variable region, comprising culturing the host cell of claim 17 under conditions for producing said heavy chain variable region, said light chain variable region, or said heavy chain variable region and said light chain variable region.
19. The method of claim 18 , further comprising isolating said heavy chain variable region, said light chain variable region, or said heavy chain variable region and said light chain variable region.
20. The method of claim 19 , further comprising formulating said heavy chain variable region, said light chain variable region, or said heavy chain variable region and said light chain variable region into a composition including at least one additional component.
21. A method of treating cancer, comprising administering the antibody of claim 1 to a patient with cancer, wherein the antibody is conjugated to a cytotoxic agent.
22. The method of claim 21 , wherein the cancer is acute myeloid leukaemia (AML).
23. The method of claim 21 , wherein the cancer is metastatic cancer.
24. The method of claim 21 , wherein the method further comprises administering an immune checkpoint modulator (ICM) to the patient.
25. A kit comprising the antibody of claim 1 and one or more reagents that allow determination of the binding of the antibody to metastatic cancer cells.
26. A method of detecting metastatic cancer cells, comprising contacting a sample suspected of containing metastatic cancer cells with an antibody of claim 1 and detecting binding of the antibody to the metastatic cancer cells.